Esketamine modulates cerebral function variations between S1 and BLA in rats with chronic pain and anxiety.

Abstract

<h4>Background</h4>The comorbidity of chronic pain and anxiety exerts a profound impact on neurological functions. This study aims to investigate the alterations in brain metabolism and functional connectivity that arise from the interaction between chronic pain and anxiety in rats. Furthermore, the potential therapeutic effects of esketamine on these alterations are examined.<h4>Methods</h4>Twelve-week-old male rats underwent spared nerve injury (SNI) surgery to establish a model of chronic pain with anxiety. Pain intensity was assessed regularly with pain thresholds responding to mechanical and thermal stimuli after surgery. Anxiety-like behaviors were evaluated on day 32 post-SNI using open field test (OFT) and elevated plus maze test (EPM). Commencing on day 29 post-SNI, they received intraperitoneal administration of esketamine at 6 mg/kg once daily for three consecutive days. Additional cohorts were used for functional magnetic resonance imaging (fMRI), nuclear magnetic resonance (NMR) spectroscopy, and brain c-Fos immunostaining on post-surgery day 32.<h4>Results</h4>Esketamine significantly alleviated SNI-induced hyperalgesia and anxiety-like behaviors, leading to reduced sensitivity to mechanical and thermal pain and a longer duration spent in the central area of the OFT, and longer time spent in the open arms of the EPM. Additionally, SNI rats showed an increased ¹³C enrichment of Glx₃ in the cerebral cortex, striatum and thalamus, while esketamine reduced Glx₃ enrichment in the cerebral cortex, indicating decreased cortical glutamate dynamics. Esketamine negated the increased functional connectivity between the right primary somatosensory cortex (S1_R) and the basolateral amygdala (BLA) induced by chronic pain and anxiety. Consistently, esketamine significantly decreased neuronal activation labelled with c-Fos⁺ cells in the S1_R and BLA following acute pain stimulation.<h4>Conclusions</h4>Esketamine alleviates SNI-induced hyperalgesia and anxiety, potentially by reducing the heightened functional connectivity between the S1_R and the BLA associated with pain and anxiety, while also normalizing glutamate metabolism in the brain. These findings suggest that esketamine may be a promising therapeutic option for managing pain and anxiety related to chronic pain conditions.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords